Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
27 January 2012Website:
http://www.verastem.comNext earnings report:
08 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 05 Jul 2024 23:13:58 GMTDividend
Analysts recommendations
Institutional Ownership
VSTM Latest News
NEW YORK, July 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Verastem, Inc. (“Verastem” or the “Company”) (NASDAQ: VSTM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
NEW YORK , July 2, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Verastem, Inc. ("Verastem" or the "Company") (NASDAQ: VSTM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, June 30, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Verastem, Inc. (“Verastem” or the “Company”) (NASDAQ: VSTM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
NEW YORK, June 22, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Verastem, Inc. (“Verastem” or the “Company”) (NASDAQ: VSTM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
NEW YORK, NY / ACCESSWIRE / June 17, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Verastem, Inc. ("Verastem" or the "Company") (NASDAQ:VSTM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, June 10, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Verastem, Inc. (“Verastem” or the “Company”) (NASDAQ: VSTM) on behalf of Verastem stockholders. Our investigation concerns whether Verastem has violated the federal securities laws and/or engaged in other unlawful business practices.
NEW YORK--(BUSINESS WIRE)---- $VSTM #Investor--The law firm of Kirby McInerney LLP is investigating potential claims against Verastem, Inc. (“Verastem” or the “Company”) (NASDAQ: VSTM). The investigation concerns whether Verastem and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices. [Click here to learn more about the investigation] On May 23, 2024, Verastem issued a press release “announc[ing] the initial interim safety and efficacy results f.
NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Verastem, Inc. (“Verastem” or the “Company”) (NASDAQ: VSTM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
NEW YORK , May 30, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Verastem, Inc. ("Verastem" or the "Company") (NASDAQ: VSTM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Verastem Oncology's stock dropped significantly after the announcement of data from the RAMP-205 study investigating avutometinib in combination with standard chemotherapy for metastatic pancreatic cancer. The study showed promising early efficacy signal with 87% response rate, but also a high rate of serious adverse events. Verastem Oncology is on track to secure a drug approval for avutometinib, but their low cash position poses a significant risk.
- 1(current)
What type of business is Verastem?
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. In addition, it has clinical collaboration agreement with Amgen, Inc. to evaluate the combination of VS-6766 with Amgen's KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.
What sector is Verastem in?
Verastem is in the Healthcare sector
What industry is Verastem in?
Verastem is in the Biotechnology industry
What country is Verastem from?
Verastem is headquartered in United States
When did Verastem go public?
Verastem initial public offering (IPO) was on 27 January 2012
What is Verastem website?
https://www.verastem.com
Is Verastem in the S&P 500?
No, Verastem is not included in the S&P 500 index
Is Verastem in the NASDAQ 100?
No, Verastem is not included in the NASDAQ 100 index
Is Verastem in the Dow Jones?
No, Verastem is not included in the Dow Jones index
When does Verastem report earnings?
The next expected earnings date for Verastem is 08 August 2024